Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

Abstract

BACKGROUND:

Nilotinib inhibits the tyrosine kinase activity of ABL1/BCR-ABL1 and KIT, platelet-derived growth factor receptors (PDGFRs), and the discoidin domain receptor. Gain-of-function mutations in KIT or PDGFRα are key drivers in most gastrointestinal stromal tumours (GISTs). This trial was designed to test the efficacy and safety of nilotinib versus imatinib as first-line therapy for patients with advanced GISTs.

METHODS:

In this randomised, open-label, multicentre, phase 3 trial (ENESTg1), participants from academic centres were aged 18 years or older and had previously untreated, histologically confirmed, metastatic or unresectable GISTs. Patients were stratified by previous adjuvant therapy and randomly assigned (1:1) via a randomisation list to receive oral imatinib 400 mg once daily or oral nilotinib 400 mg twice daily. The primary endpoint was centrally reviewed progression-free survival. Efficacy endpoints were assessed by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00785785.

FINDINGS:

Because the futility boundary was crossed at a preplanned interim analysis, trial accrual terminated in April, 2011. Between March 16, 2009, and April 21, 2011, 647 patients were enrolled; of whom 324 were allocated nilotinib and 320 were allocated imatinib. At final analysis of the core study (data cutoff, October, 2012), 2-year progression-free survival was higher in the imatinib group (59·2% [95% CI 50·9-66·5]) than in the nilotinib group (51·6% [43·0-59·5]; hazard ratio 1·47 [95% CI 1·10-1·95]). In the imatinib group, the most common grade 3-4 adverse events were hypophosphataemia (19 [6%]), anaemia (17 [5%]), abdominal pain (13; 4%), and elevated lipase level (15; 5%), and in the nilotinib group were anaemia (18; 6%), elevated lipase level (15; 5%), elevated alanine aminotransferase concentration (12; 4%), and abdominal pain (11; 3%). The most common serious adverse event in both groups was abdominal pain (11 [4%] in the imatinib group, 14 [4%] in the nilotinib group).

INTERPRETATION:

Nilotinib cannot be recommended for broad use to treat first-line GIST. However, future studies might identify patient subsets for whom first-line nilotinib could be of clinical benefit.

FUNDING:

Novartis Pharmaceuticals.

• Authors: Jean-Yves Blay, Lin Shen, Yoon-Koo Kang, Piotr Rutkowski, Shukui Qin, Dmitry Nosov, Desen Wan, Jonathan Trent, Vichien Srimuninnimit, Zsuzsanna Pápai, Axel Le Cesne, Steven Novick, Lilia Taningco, Shuyuan Mo, Steven Green, Peter Reichardt, George D Demetri
• Journal: The Lancet. Oncology (Lancet Oncol) Vol. 16 Issue 5 Pg. 550-60 (May 2015) ISSN: 1474-5488 [Electronic] England
• PMID: 25882987 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Benzamides
• Piperazines
• Pyrimidines
• Imatinib Mesylate
• nilotinib

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Benzamides (administration & dosage)
• Disease-Free Survival
• Female
• Gastrointestinal Stromal Tumors (drug therapy, pathology)
• Humans
• Imatinib Mesylate
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neoplasm Metastasis
• Piperazines (administration & dosage)
• Pyrimidines (administration & dosage)
• Treatment Outcome